State lawmakers have advanced measures that could expand access to psilocybin drugs and MDMA in treating certain disorders.
One bill would fund a $30 million research program to study psilocybin mushrooms in treating post-traumatic stress disorder and depression.
Another would allow MDMA, also known as ecstasy, to be used as a prescription medication if the federal government removes its Schedule 1 drug status.
Both drugs have been unable to receive federal funding for research due to their Schedule 1 classification.
The measures require full House approval, but have received bipartisan support in committees.
